Ranbaxy Laboratories reported a 89.91 per cent decline in its consolidated net profit at Rs.125.75 crore for the first quarter ended March 31, 2013, mainly on account of absence of contribution from exclusivities. It had posted a net profit of Rs.1,246.76 crore in the year-ago period, Ranbaxy Laboratories said in a statement.

Net sales declined to Rs.2,439.82 crore from Rs.3,708.97 crore

Lupin

Lupin, on Wednesday, posted nearly three-fold increase in consolidated net profit at Rs.408.1 crore for the fourth quarter ended March 31, 2013, mainly on account of robust sales in the U.S. and India. The company had posted a net profit of Rs.155.6 crore in the January-March quarter of 2011-12.

Net sales rose to Rs.2,537.4 crore from Rs.1,883.2 crore,the company said in a statement.

For the entire 2012-13 fiscal, the company posted a net profit of Rs.1,314.2 crore against Rs.867.6 crore in 2011-12. Net sales rose to Rs.9,461.6 crore from Rs.6,959.7 crore.

The company’s board recommended a dividend of Rs.4 per share of the face value of Rs.2 each for the year ended March 31, 2013.

Finolex Industries

Finolex Industries reported a 41.2 per cent growth in net profit at Rs.79.35 crore for the fourth quarter ended March 31, 2013, against Rs.56.19 crore in the year-ago period, the company said in a release. Sales grew by 6 per cent to Rs.629.59 crore from Rs.593.01 crore.

The net profit for the whole of 2012-13 grew by 81.15 per cent to Rs.136.14 crore from Rs.75.15 crore in FY’12. The board of directors has recommended a dividend of Rs.5.50 per share for 2012-13.

KEC International reported a consolidated net loss of Rs.13.93 crore for the fourth quarter ended March 31, 2013.

It had reported a net profit of Rs.74.42 crore during the corresponding quarter of 2011-12.

Net sales increased marginally by 4 per cent to Rs.2,104.67 crore from Rs.2,024.18 crore, it said in a filing to the BSE.

For the year ended March, 2013, the net profit declined by nearly 69 per cent to Rs.65.04 crore from Rs.209.3 crore in 2011-12. However, net sales increased by 20.19 per cent during the fiscal to Rs.6854.19 crore.

The company's board has recommended a dividend of 55 paise per share.

RELATED NEWS

No plans to reduce workforce: Ranbaxy October 2, 2013

More In: Industry | Business